Clinical Trial Update: A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia [Phase 4]

View source ↗

Summary

A Phase 4 trial protocol to assess whether a single-dose CERVAVAC Quadrivalent HPV vaccine is non-inferior in immunogenicity to Gardasil Quadrivalent across age…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Human Papillomavirus Infection

Drugs mentioned

• CERVAVAC Quadrivalent HPV Vaccine
• Gardasil Quadrivalent HPV Vaccine (HPV quadrivalent vaccine)

Snippet

Sponsor: International Agency for Research on Cancer | Conditions: Vaccine Effectiveness, HPV Vaccination | Phase 4 | Status: NOT_YET_RECRUITING